[go: up one dir, main page]

IL146914A0 - Pharmaceutical compositions containing (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives - Google Patents

Pharmaceutical compositions containing (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives

Info

Publication number
IL146914A0
IL146914A0 IL14691400A IL14691400A IL146914A0 IL 146914 A0 IL146914 A0 IL 146914A0 IL 14691400 A IL14691400 A IL 14691400A IL 14691400 A IL14691400 A IL 14691400A IL 146914 A0 IL146914 A0 IL 146914A0
Authority
IL
Israel
Prior art keywords
trihalomethylphenoxy
halophenyl
acetic acid
pharmaceutical compositions
compositions containing
Prior art date
Application number
IL14691400A
Other languages
English (en)
Original Assignee
Metabolex Inc
Diatex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23270381&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL146914(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Metabolex Inc, Diatex Inc filed Critical Metabolex Inc
Publication of IL146914A0 publication Critical patent/IL146914A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14691400A 1999-06-04 2000-06-02 Pharmaceutical compositions containing (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives IL146914A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/325,997 US6262118B1 (en) 1999-06-04 1999-06-04 Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
PCT/US2000/015235 WO2000074666A2 (fr) 1999-06-04 2000-06-02 Utilisation de derives d'acide acetique (-) (3-trihalomethylphenoxy) (4-halophenyl) permettant de traiter la resistance insulinique, les diabetes de type 2, l'hyperlipidemie et l'hyperuricemie

Publications (1)

Publication Number Publication Date
IL146914A0 true IL146914A0 (en) 2002-08-14

Family

ID=23270381

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14691400A IL146914A0 (en) 1999-06-04 2000-06-02 Pharmaceutical compositions containing (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives
IL146914A IL146914A (en) 1999-06-04 2001-12-04 Pharmaceutical preparations containing a history of acid (-) (3 - trihalomethylphenoxy) (4 - halonfill) Acetate
IL187605A IL187605A (en) 1999-06-04 2007-11-25 Pharmaceutical preparations containing a history of acid (-) (3 - trihalomethylphenoxy) (4 - lupenil) Acetate and their use in the preparation of a drug for the treatment of hyperuricemia

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL146914A IL146914A (en) 1999-06-04 2001-12-04 Pharmaceutical preparations containing a history of acid (-) (3 - trihalomethylphenoxy) (4 - halonfill) Acetate
IL187605A IL187605A (en) 1999-06-04 2007-11-25 Pharmaceutical preparations containing a history of acid (-) (3 - trihalomethylphenoxy) (4 - lupenil) Acetate and their use in the preparation of a drug for the treatment of hyperuricemia

Country Status (32)

Country Link
US (6) US6262118B1 (fr)
EP (2) EP1183020B1 (fr)
JP (2) JP4685300B2 (fr)
KR (2) KR100779787B1 (fr)
CN (2) CN1189168C (fr)
AR (1) AR042574A1 (fr)
AT (2) ATE524173T1 (fr)
AU (1) AU775909C (fr)
BR (1) BR0011342A (fr)
CA (2) CA2371723C (fr)
CL (1) CL2011001971A1 (fr)
CO (1) CO5170453A1 (fr)
CY (1) CY1112861T1 (fr)
CZ (1) CZ20014341A3 (fr)
DE (1) DE60030109T2 (fr)
DK (2) DK1183020T3 (fr)
ES (2) ES2269151T3 (fr)
HK (1) HK1045111B (fr)
HU (1) HUP0201611A3 (fr)
IL (3) IL146914A0 (fr)
MX (1) MXPA01012435A (fr)
NO (1) NO20015909L (fr)
NZ (2) NZ515902A (fr)
PE (1) PE20010220A1 (fr)
PT (2) PT1183020E (fr)
RU (2) RU2281762C2 (fr)
SA (1) SA00210535B1 (fr)
SK (1) SK17562001A3 (fr)
TW (1) TWI264303B (fr)
UA (1) UA74147C2 (fr)
WO (1) WO2000074666A2 (fr)
ZA (3) ZA200300888B (fr)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624194B1 (en) * 1999-06-04 2003-09-23 Metabolex, Inc. Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US20080108825A1 (en) * 1999-11-08 2008-05-08 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
US20080103302A1 (en) * 2000-02-04 2008-05-01 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
AU2001253373A1 (en) * 2000-04-12 2001-10-30 Puracyp Compositions and methods for induction of proteins involved in xenobiotic metabolism
PE20020323A1 (es) * 2000-08-22 2002-06-13 Novartis Ag COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE)
AU2002251978B2 (en) 2001-02-09 2007-07-19 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
ATE422884T1 (de) * 2002-06-03 2009-03-15 Novartis Pharma Gmbh Verwendung von substituierten cyanopyrrolidinen zur behandlung von hyperlipidämie
WO2003103633A1 (fr) * 2002-06-10 2003-12-18 Elan Pharma International, Ltd. Preparation de sterols nanoparticulaires et nouvelles combinaisons de sterols
CN100525757C (zh) * 2003-06-20 2009-08-12 麦它波莱克斯股份有限公司 α-(苯氧基)苯乙酸衍生物的拆分
MXPA05013981A (es) * 2003-06-20 2006-03-02 Metabolex Inc Resolucion de derivados de acido a- (fenoxi) fenilacetico.
US7199259B2 (en) * 2003-06-20 2007-04-03 Metabolex, Inc. Resolution of α-(phenoxy)phenylacetic acid derivatives
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
KR20070011312A (ko) * 2004-02-18 2007-01-24 메타볼렉스, 인코포레이티드 항당뇨병제로서 알파-(트리플루오로메틸-치환된 아릴옥시,아릴아미노, 아릴티오 또는아릴메틸)-트리플루오로메틸-치환된 페닐아세트산 및 이의유도체
US7816367B2 (en) 2004-02-27 2010-10-19 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
EP1751120A4 (fr) * 2004-05-25 2010-05-05 Metabolex Inc Triazoles substitués comme modulateurs de ppar et méthodes de préparation
WO2005115384A2 (fr) * 2004-05-25 2005-12-08 Metabolex, Inc. Triazoles substitués bicyliques comme modulateurs de ppar et méthodes de préparation
EP1865778A4 (fr) * 2005-03-21 2010-12-08 Metabolex Inc Methodes empechant la formation d'oedeme dans le traitement de troubles metaboliques, inflammatoires et cardio-vasculaires
US8203019B2 (en) * 2005-04-20 2012-06-19 Metabolex, Inc. Crystalline solid and amorphous forms of (−)- halofenate and methods related thereto
US20090137626A1 (en) * 2005-07-12 2009-05-28 Akira Okuno Pharmaceutical Composition Containing PPARgamma Agonist
EP1906934A4 (fr) * 2005-07-14 2012-03-07 Franco Folli Schéma posologique quotidien pour le traitement du diabète, de l obésité, du syndrome métabolique et du syndrome des ovaires polykystiques
US7432394B2 (en) * 2005-09-23 2008-10-07 Metabolex, Inc. Resolution of α-(phenoxy) phenylacetic acid derivatives with naphthyl-alkylamines
US7714131B2 (en) * 2005-09-23 2010-05-11 Metabolex, Inc. Process for the stereoselective preparation of (−)-halofenate and derivatives thereof
TW200806285A (en) * 2006-03-30 2008-02-01 Santen Pharmaceutical Co Ltd Therapeutic agent for keratoconjunctive problem
WO2007127440A2 (fr) * 2006-04-27 2007-11-08 Intezyne Technologies, Inc. Poly(éthylène glycol) contenant des groupes amino-protecteurs acides-labiles et leurs utilisations
KR100788454B1 (ko) * 2006-06-15 2007-12-24 대원제약주식회사 속효성이 증진된 나테글리니드를 유효성분으로 함유하는약제학적 조성물
BRPI0716134A2 (pt) 2006-09-07 2013-09-17 Nycomed Gmbh tratamento de combinaÇço para diabetes mellitus
WO2009052182A1 (fr) 2007-10-15 2009-04-23 Jbs United, Inc. Procédé permettant d'accroître la performance d'une progéniture
WO2008149345A2 (fr) 2007-06-04 2008-12-11 Ben-Gurion University Of The Negev Research And Development Authority Composés triarylés et compositions les comprenant
US20110021468A1 (en) * 2007-07-03 2011-01-27 Joslin Diabetes Center, Inc. Treatment of cardiovascular disease with salicylates
WO2009046371A1 (fr) * 2007-10-05 2009-04-09 Metabolex, Inc. Procédés de traitement de maladies métaboliques
WO2009121940A1 (fr) * 2008-04-03 2009-10-08 Janssen Pharmaceutica Nv Procédé de préparation de l'ester 2-acétylamino-éthylique de l'acide (-)-(4-chlorophényl)-(3-trifluorométhylphénoxy)-acétique
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
WO2014037832A2 (fr) 2012-09-06 2014-03-13 Mahesh Kandula Compositions et méthodes de traitement de l'épilepsie et de maladies neurologiques
CN104066323A (zh) * 2011-11-04 2014-09-24 西玛贝医药公司 用于治疗患者亚群中痛风的方法
US9023856B2 (en) 2011-11-04 2015-05-05 Cymabay Therapeutics, Inc. Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent
CN109908124A (zh) * 2011-11-04 2019-06-21 西玛贝医药公司 利用卤芬酯或卤芬酸以及第二尿酸降低剂治疗痛风患者中高尿酸血症的方法
ES2698396T3 (es) * 2011-11-04 2019-02-04 Cymabay Therapeutics Inc Métodos para tratar los brotes de gota
US9060987B2 (en) 2011-11-04 2015-06-23 Cymabay Therapeutics, Inc. Methods for treating gout flares
EP2836209A4 (fr) * 2012-04-13 2015-11-25 Cymabay Therapeutics Inc Méthode de traitement de l'hyperuricémie, faisant appel à l'halofénate ou à l'acide halofénique et à un agent anti-inflammatoire, chez les patients souffrant de goutte
WO2013168021A1 (fr) 2012-05-07 2013-11-14 Mahesh Kandula Compositions et méthodes pour le traitement des troubles neuromusculaires et des troubles neurodégénératifs
WO2013167990A1 (fr) 2012-05-07 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de la dépression
EP2847169A4 (fr) 2012-05-07 2015-09-30 Cellix Bio Private Ltd Compositions et méthodes de traitement de troubles neurologiques
WO2013168025A1 (fr) 2012-05-08 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement des maladies de coagulation du sang
WO2013167993A1 (fr) 2012-05-08 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de troubles neurologiques dégénératifs
WO2013167991A1 (fr) 2012-05-08 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de troubles métaboliques
WO2013168023A1 (fr) 2012-05-08 2013-11-14 Mahesh Kandula Compositions et méthodes pour le traitement de la maladie de parkinson
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013168011A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de la douleur chronique
CA2873089A1 (fr) * 2012-05-10 2013-11-14 Cellixbio Private Limited Compositions et methodes de traitement du syndrome metabolique
WO2013168014A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de la polyneuropathie amyloïde familiale
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
WO2013168012A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de troubles respiratoires
WO2013168016A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement du syndrome métabolique
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168002A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement d'affections neurologiques
WO2013168033A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et methodes pour le traitement de maladies neurologiques
CA2873098A1 (fr) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions et methodes pour le traitement de la sclerose en plaques
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175347A2 (fr) 2012-05-23 2013-11-28 Mahesh Kandula Compositions et méthodes pour le traitement de troubles respiratoires
AU2013264894B2 (en) 2012-05-23 2015-11-19 Cellix Bio Private Limited Compositions and methods for treatment of inflammatory bowel disease
WO2013175377A2 (fr) 2012-05-23 2013-11-28 Mahesh Kandula Compositions et méthodes pour le traitement de la mucosite
WO2013175376A2 (fr) 2012-05-23 2013-11-28 Mahesh Kandula Compositions et méthodes de traitement de la douleur locale
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (fr) 2012-08-03 2014-02-06 Mahesh Kandula Compositions et méthodes pour le traitement de la migraine et de maladies neurologiques
WO2014037833A2 (fr) 2012-09-06 2014-03-13 Mahesh Kandula Compositions et méthodes de traitement d'une inflammation et de troubles lipidiques
AU2013311349A1 (en) 2012-09-08 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (fr) 2013-06-04 2018-09-05 Cellixbio Private Limited Compositions et procédés de traitement du diabète et du pré-diabète
CN106061940A (zh) 2013-11-05 2016-10-26 本古里安大学内盖夫研究发展局 治疗糖尿病和由其引发的并发疾病的化合物
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016110865A1 (fr) 2015-01-06 2016-07-14 Cellix Bio Private Limited Compositions et méthodes pour le traitement d'une inflammation et de la douleur
SG11201706952VA (en) 2014-09-26 2017-10-30 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
ES2799309T3 (es) 2014-09-29 2020-12-16 Cellix Bio Private Ltd Compuestos y composiciones para el tratamiento de esclerosis múltiple
SG11201703369WA (en) 2014-10-27 2017-05-30 Cellix Bio Private Ltd Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
JP6192142B2 (ja) * 2016-09-13 2017-09-06 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 痛風発赤の治療方法
JP6368756B2 (ja) * 2016-10-20 2018-08-01 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
CN109369471A (zh) * 2018-12-10 2019-02-22 石家庄度恩医药科技有限公司 一种光学活性R-4-氯-α-(3-三氟甲基苯氧基)苯乙酸的制备方法
WO2021236395A1 (fr) 2020-05-18 2021-11-25 Cymabay Therapeutics, Inc. Sel de choline cb-0406
US20210355065A1 (en) 2020-05-18 2021-11-18 Cymabay Therapeutics, Inc. CB-0406 tromethamine salt
USD1107573S1 (en) * 2022-08-19 2025-12-30 Honeywell International Inc. Aerosol sensor

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3517051A (en) * 1964-03-20 1970-06-23 Merck & Co Inc Phenoxy substituted phenylacetic acids
US3378582A (en) * 1964-03-20 1968-04-16 Merck & Co Inc (alpha-phenoxy)-and (alpha-phenylthio)-omegaphenyl-alkanoic acids
NL6712585A (fr) 1966-10-03 1968-04-04
US3517050A (en) 1966-10-03 1970-06-23 Merck & Co Inc Ester and amide derivative of (3-trifluoromethylphenoxy) (4 - halophenyl)acetic acid
DK133742B (da) 1970-10-30 1976-07-12 Merck & Co Inc Fremgangsmåde til fremstilling af 2-acetamidoethyl-(3-trifluormethylphenoxy)-(4-chlorphenyl)-acetat.
US3923855A (en) 1972-07-13 1975-12-02 Merck & Co Inc 2-sulfonyloxyethyl 3-trifluoromethylphenoxy-4{40 -chlorophenyl acetate
NL7309039A (fr) * 1972-07-13 1974-01-15
US3860628A (en) * 1972-07-13 1975-01-14 Merck & Co Inc Cyanomethyl(3-trifluoromethylphenoxy)(4-chlorophenyl)acetate
US3953490A (en) 1972-07-13 1976-04-27 Merck & Co., Inc. Preparation of (3-trifluoromethylphenoxy)(4-chlorophenyl)acetonitrile
NL7309571A (fr) 1972-07-28 1974-01-30
US4110351A (en) 1973-04-02 1978-08-29 Richardson-Merrell Inc. Hypolipidemic agents RO- or RS- substituted furoic acids, esters and salts
IL48707A0 (en) 1974-12-30 1976-02-29 Synthelabo Novel phenylacetic acid derivatives,their preparation and pharmaceutical compositions containing them
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US4532135A (en) * 1981-02-09 1985-07-30 Edwards K David G Renoprotective treatments employing vasodilator compounds
DE3525284A1 (de) * 1985-07-16 1987-01-29 Boehringer Mannheim Gmbh Neue carbonsaeurederivate, verfahren zu ihrer herstellung, ihre verwendung sowie arzneimittel, die diese verbindungen enthalten
US5028052A (en) * 1990-05-11 1991-07-02 Miller Omer E Golf mat
DE4111026A1 (de) 1991-04-05 1992-10-08 Boehringer Mannheim Gmbh Optisch aktive carbonsaeuren sowie diese enthaltende arzneimittel
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
JPH0927811A (ja) * 1995-07-13 1997-01-28 Fujitsu Ltd 輻輳監視制御装置
WO1997010813A1 (fr) 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Antagonistes de ppar gamma pour le traitement de l'obesite
US5859051A (en) 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US5716987A (en) * 1996-06-21 1998-02-10 Bristol-Myers Squibb Company Prophylactic and therapeutic treatment of skin sensitization and irritation
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US6624194B1 (en) * 1999-06-04 2003-09-23 Metabolex, Inc. Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6555577B1 (en) 2000-01-28 2003-04-29 Novo Nordisk A/S Compounds, their preparation and use
US6576662B2 (en) 2000-05-05 2003-06-10 Dr. Reddy's Laboratories Limited Compounds having anticancer activity : process for their preparation and pharmaceutical compositions containing them
US6693094B2 (en) 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
CN1319938C (zh) 2002-06-20 2007-06-06 阿斯特拉曾尼卡有限公司 治疗胰岛素抵抗的邻位取代的苯甲酸衍生物
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
WO2004078113A2 (fr) * 2003-03-04 2004-09-16 Pharmacia Corporation Traitement et prevention de l'obesite au moyen d'inhibiteurs de cox-2 seul ou en combinaison avec des agents d'amaigrissement
US7199259B2 (en) * 2003-06-20 2007-04-03 Metabolex, Inc. Resolution of α-(phenoxy)phenylacetic acid derivatives
MXPA05013981A (es) 2003-06-20 2006-03-02 Metabolex Inc Resolucion de derivados de acido a- (fenoxi) fenilacetico.
US20070207983A1 (en) 2004-03-16 2007-09-06 Nieuwenhuizen Willem F Use of Sphingolipids in the Treatment and Prevention of Type 2 Diabetes Mellitus, Insulin Resistance and Metabolic Syndrome
WO2007102861A2 (fr) 2005-12-02 2007-09-13 Sirtris Pharmaceuticals, Inc. Modulateurs de kinases de type cdc2 (clks) et leurs procédés d'utilisation
US7635710B2 (en) 2006-02-15 2009-12-22 Neurim Pharmaceuticals (1991) Ltd. Pyrone-indole derivatives and process for their preparation

Also Published As

Publication number Publication date
HK1045111B (en) 2006-11-17
US20070270490A1 (en) 2007-11-22
NO20015909L (no) 2002-01-15
RU2281762C2 (ru) 2006-08-20
DK1614418T3 (da) 2011-10-17
PT1183020E (pt) 2006-11-30
PE20010220A1 (es) 2001-02-23
NZ515902A (en) 2004-02-27
EP1183020B1 (fr) 2006-08-16
AR042574A1 (es) 2005-06-29
US20050075396A1 (en) 2005-04-07
NZ528266A (en) 2005-07-29
ZA200109973B (en) 2003-02-04
JP4685300B2 (ja) 2011-05-18
WO2000074666A3 (fr) 2001-11-08
US6613802B1 (en) 2003-09-02
JP2007099784A (ja) 2007-04-19
WO2000074666A2 (fr) 2000-12-14
CA2751187A1 (fr) 2000-12-14
IL187605A0 (en) 2008-03-20
CN1189168C (zh) 2005-02-16
JP2003501383A (ja) 2003-01-14
US8354448B2 (en) 2013-01-15
IL187605A (en) 2012-07-31
EP1183020A2 (fr) 2002-03-06
KR100721219B1 (ko) 2007-05-22
CA2371723C (fr) 2012-08-21
KR20020025063A (ko) 2002-04-03
ATE336235T1 (de) 2006-09-15
ATE524173T1 (de) 2011-09-15
CN1368879A (zh) 2002-09-11
CO5170453A1 (es) 2002-06-27
CN1660060A (zh) 2005-08-31
DE60030109T2 (de) 2007-02-15
TWI264303B (en) 2006-10-21
EP1614418B1 (fr) 2011-09-14
CA2751187C (fr) 2014-04-22
EP1614418A1 (fr) 2006-01-11
DK1183020T3 (da) 2006-11-27
KR100779787B1 (ko) 2007-11-28
AU775909B2 (en) 2004-08-19
SK17562001A3 (sk) 2002-10-08
US6262118B1 (en) 2001-07-17
AU5316200A (en) 2000-12-28
ZA200300888B (en) 2004-06-30
ES2371476T3 (es) 2012-01-03
RU2005132222A (ru) 2007-04-27
KR20060122983A (ko) 2006-11-30
HUP0201611A3 (en) 2003-03-28
ZA200300889B (en) 2004-08-25
NO20015909D0 (no) 2001-12-03
MXPA01012435A (es) 2003-09-10
ES2269151T3 (es) 2007-04-01
US20100093853A1 (en) 2010-04-15
CL2011001971A1 (es) 2012-03-30
HK1087616A1 (en) 2006-10-20
JP4685808B2 (ja) 2011-05-18
BR0011342A (pt) 2002-03-05
CA2371723A1 (fr) 2000-12-14
CZ20014341A3 (cs) 2002-11-13
CN100379412C (zh) 2008-04-09
HUP0201611A2 (en) 2002-10-28
IL146914A (en) 2008-07-08
SA00210535B1 (ar) 2006-10-11
HK1045111A1 (en) 2002-11-15
CY1112861T1 (el) 2016-04-13
UA74147C2 (uk) 2005-11-15
US6646004B1 (en) 2003-11-11
AU775909C (en) 2005-06-30
PT1614418E (pt) 2011-11-21
DE60030109D1 (de) 2006-09-28

Similar Documents

Publication Publication Date Title
IL146914A0 (en) Pharmaceutical compositions containing (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives
HUP0200807A3 (en) Substituted propionic acid derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0201291A2 (en) Di-aryl acid derivatives as ppar receptor ligands and pharmaceutical compositions containing them
HUP0100819A3 (en) Aminophenoxyacetic acid derivatives as neuroprotectants and pharmaceutical compositions containing them
IL145732A0 (en) α-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
HUP0103376A3 (en) New 3-aryl-2-hydroxypropionic acid derivative, pharmaceutical compositions containing it, process for their preparation and their use
HUP0200997A3 (en) Tri-aryl acid derivatives as ppar receptor ligands and pharmaceutical compositions containing them
IL161431A0 (en) beta-PHENYL-alpha-OXYSUBSTITUTED PROPIONIC ACID DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
AU1928501A (en) Formulations for pharmaceutical agents ionizable as free acids or free bases
HUP0200863A3 (en) Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them and their use
IL148134A0 (en) Novel derivatives of dicarboxylic acid having pharmaceutical properties
IL144198A0 (en) Pyrazolecarboxylic acid derivatives, their preparation, pharmaceutical compositions containing them
GB0028088D0 (en) Pharmaceutical compositions
GB0001662D0 (en) Pharmaceutical compositions
HUP0202788A3 (en) Indolyl-3-glyoxylic acid derivatives serving as antitumor agents and pharmaceutical compositions containing them
AU4304400A (en) Novel pharmaceutical compositions comprising 2-isoxazole-8-aminotetralin derivatives
HUP0203339A3 (en) Ciclesonide contained pharmaceutical composition for application to mucosa
HUP0103788A3 (en) Processes for the preparation of 5-hydroxy-3-oxopentanoic acid derivatives
IL148725A0 (en) Aqueous pharmaceutical compositions containing circlesonide
IL158172A0 (en) Pharmaceutical compositions containing (-)-hydroxycitric acid
IL149470A0 (en) Pharmaceutical compositions containing carboxamidoadenosine derivatives
HUP0200311A3 (en) Use of aroyl- or arylalkanoylpyridazines for preparation of pharmaceutical compositions
HUP0203454A3 (en) Novel fusidic acid derivatives, pharmaceutical compositions containing them and their use
AU3445400A (en) The preparation of (trans)-4-amino-2-cyclopentene-1-carboxylic acid derivatives
HUP0201549A2 (en) Quinolinecarboxylic acid derivative or salts thereof and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
KB Patent renewed